Abstract
Nephrology practices currently are amidst a genetics/genomics revolution where clinical molecular screening has transitioned from analysis of single genes (Sanger sequencing) to global approaches (next-generation sequencing). Two approaches are now generally employed in nephrology, exome sequencing (screening the coding regions of all genes) followed by analysis of genes known to be associated with monogenic kidney disease, or just screening those genes or a phenotypically distinct subset (e.g., cystic kidney disease or nephrolithiasis) via targeted gene panels (Table 1).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
